An Observational Study of Peginterferon-alfa-2a (Pegasys) and Ribavirin (Copegus) on Predictive Values of RVR on Sustained Virological Response (SVR) in Different Stage of Liver Fibrosis in Treatment-naive Patients With Genotype 1 Chronic Hepatitis C
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 05 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Oct 2013 Planned End Date changed from 1 Mar 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.